{"entity":{"id":"nct07131202","kind":"trial","name":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of FL115+PD-1 in advanced solid tumours, run by Suzhou Forlong Biotechnology Co., Ltd, now recruiting.","summary":"A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07131202 by Suzhou Forlong Biotechnology Co., Ltd, with 130 participants planned, started 2026-01-08 and due to reach its primary completion in 2026-12-05. Interventions recorded: FL115+PD-1.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07131202","url":"https://clinicaltrials.gov/study/NCT07131202"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["suzhou-forlong-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07131202","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, and Pharmacodynamics of FL115 in Combination With a PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors","sponsor":"Suzhou Forlong Biotechnology Co., Ltd","enrolled":130,"outcomes":[]},"route":"/trials/nct07131202/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"suzhou-forlong-biotechnology","kind":"company","name":"Suzhou Forlong Biotechnology","route":"/companies/suzhou-forlong-biotechnology/"}]}}